Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Auxilium and QLT entered a definitive agreement to merge in a deal valued at US$850 million; transaction expected to drive shareholder value by accelerating…
On June 26, 2014, Auxilium and QLT announced a definitive agreement to merge in a deal valued at US$850 million; Auxilium shareholders would own approximately…
QLT announced merger termination after Auxilium accepted Endo's superior proposal; QLT received $28.4M termination fee and chairman Jason Aryeh stated company…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Auxilium and Vancouver-based QLT announced a $850M tax-inversion reverse merger that would have left Auxilium shareholders owning 76% of the combined Canadian-domiciled entity. Terminated October 9, 2014 when Auxilium accepted a superior $2.6B bid from Endo; QLT received a $28.4M termination fee.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Auxilium Pharmaceuticals, Inc. / QLT Inc. (this deal) | 2014 | $850M | — |
| Johnson & Johnson / Abbott Medical Optics | 2003 | $4.3B | 70 |
| Johnson & Johnson / Abbott Laboratories (Abbott Medical Optics) | 2016 | $4.3B | 66 |
| Merck & Co. Inc. / EyeBio Ltd. | 2024 | $3.0B | 61 |
| Viatris / Oyster Point Pharma, Inc. | 2022 | $299M | 58 |
| Teva Pharmaceutical Industries Ltd. / Samsung Bioepis Co., Ltd. | 2026 | — | 51 |
| EyeTech Pharmaceuticals Inc. / Gilead Sciences Inc. (NX-1838 license) | 2000 | $32M | 47 |
← Browse all deals · How we score deals
More: 2014 deals · Ophthalmology deals